# Assess and treat catatonia using this systematic approach

Brian Holoyda, MD, MPH, and Glen Xiong, MD

atatonia is a neuropsychiatric condition with varying presentations that involve behavioral, motoric, cognitive, affective, and, occasionally, autonomic disturbances. Underlying causes of the syndrome include:

- mood disorders
- psychotic disorders
- neurologic disease
- general medical conditions
- metabolic abnormalities
- drug intoxication or withdrawal.

Often under-recognized, catatonia poses several medical risks for patients, including:

- deep vein thrombosis and pulmonary embolism
- pressure sores or ulcers
- muscle contractures
- nutritional deficiencies and dehydration from decreased oral intake.<sup>1</sup>

Prompt recognition, assessment, and treatment are vital.

We recommend the following systematic approach to evaluate and treat catatonia (*Table, page 66*).

#### **Assess**

Appropriate assessment of catatonia requires recognition of the array of potential underlying causes of the syndrome.

#### Obtain a complete history, including:

- · recent changes in behavior
- past psychiatric illness and hospitalization
- past or current neurologic or medical disease
- prescription and illicit drug use.

Collateral informants, such as family members and caregivers, could pro-

vide valuable information. This history could reveal causative factors and identify appropriate targets for treatment.

#### Physical and mental status examinations

can help characterize the type and severity of motoric and behavioral symptoms, such as rigidity, waxy flexibility, negativism, automatic obedience, ambitendency, and perseveration. Monitoring vital signs is crucial because of the risk of medical complications and malignant catatonia, which can be lethal if not treated.

Laboratory testing and imaging might be indicated to rule out medical causes, such as infection, metabolic disturbances, drug intoxication and withdrawal, and acute neurologic etiologies.

#### Rate

#### Identify and rate symptom severity.

After determining that a patient has catatonia, consider using a standardized instrument, such as the Bush Francis Catatonia Rating Scale (BFCRS),<sup>2</sup> to assess the patient's type of symptoms and degree of impairment. Scores obtained on

## Every issue of Current Psychiatry has its 'Pearls'

#### Yours could be found here.

Read the 'Pearls' guidelines for manuscript submission at CurrentPsychiatry.com, or request a copy from Senior Editor Patrice Kubik at pkubik@frontlinemedcom.com. Then, share with your peers a 'Pearl' of wisdom from your years of practice. Dr. Holoyda is a PGY-5 Forensic Psychiatry Fellow in the Forensic Psychiatry Fellowship Training Program, and Dr. Xiong is Associate Professor, Department of Psychiatry and Behavioral Sciences, University of California, Davis School of Medicine, Sacramento, California.

#### Disclosures

The authors report no financial relationships with any company whose products are mentioned in this article or manufacturers of competing products.

Although there are no largescale published data, ECT and benzodiazepines are the mainstays of treatment for catatonia

### Systematic approach to evaluating and treating catatonia

Assess. Obtain a complete history, conduct physical and mental status examinations, and acquire labs or imaging to identify etiology of catatonia

Rate. Identify and rate the symptoms of catatonia to ensure adequate monitoring of symptoms over time

Treat and monitor. Treat early with benzodiazepines and monitor for improvement. Use electroconvulsive therapy for patients who do not respond or demonstrate limited response to benzodiazepines

such instruments can be tracked as the patient receives treatment. Although the BFCRS is imperfect because of ambiguous symptom descriptions and because symptoms can remain after effective treatment, it is the most widely researched catatonia scale.

#### **Treat and monitor**

Although there are no published data from large-scale, randomized, controlled trials, clinical experience shows that the mainstays of treatment still are benzodiazepines and electroconvulsive therapy (ECT). A benzodiazepine challenge of IV lorazepam, 2 mg, can lead to rapid, substantial symptomatic relief with relatively low risk of harm. An estimated 50% to 70% of patients with catatonia respond within 5 days to IV lorazepam, 2 mg, every 3 to 8 hours.3

When patients do not respond to benzodiazepines, consider ECT. For patients with medical, neurologic, and toxic metabolic causes of catatonia, treat the underlying disturbance first.

#### References

- 1. Clinebell K, Azzam PN, Gopalan P, et al. Guidelines for preventing common medical complications of catatonia: case report and literature review. J Clin Psychiatry. 2014;75(6):644-651.
- 2. Bush G, Fink M, Petrides G, et al. Catatonia. I. Rating scale and standardized examination. Acta Psychiatr Scand. 1996:93(2):129-136.
- 3. Fink M. Catatonia: syndrome or schizophrenia subtype? Recognition and treatment. J Neural Transmission (Vienna). 2001;108(6):637-644.

